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Introduction
The inhibition of cytochrome P4503A (CYP3A) enzymes at the intestine and liver is responsible for many clinically important drug-drug interactions (DDIs) (Gomez et al., 1995; Gorski et al., 1998; Galetin et al., 2008) . It is now a standard practice during drug development to predict the ability of candidate drugs to inhibit the cytochrome P450s, including CYP3As, using in vitro enzyme kinetic data generated from human liver microsomes (HLMs) (Bjornsson et al., 2003a; Bjornsson et al., 2003b) . These in vitro CYP inhibition parameters have facilitated the assessment of risk and predicted the potential magnitude of DDI when combined with measures or predictions of human drug exposure but the approach is time consuming and has significant limitations. The state-of-the art prediction of an in vivo CYP-mediated, inhibitory DDI requires estimation of the reversible inhibition constant (K i ), the irreversible inhibition parameters (K I and k inact ), the fraction unbound in plasma (f u,p ) and the fraction unbound in the microsomal system (f u,mic ) (Wang et al., 2004) . Sophisticated models using static or dynamic drug concentration have been developed to integrate this data set and predict an in vivo DDI for a given drug dosing regimen (Obach et al., 2006; Einolf, 2007; Fahmi et al., 2009; Xu et al., 2009; Rowland Yeo et al., 2010) . However, the resulting predictions often result in false positives, false negatives and fail to correctly categorize inhibitors as weak, moderate and strong in vivo inhibitors (Xu et al., 2009 ). Consequently, a consensus on the most appropriate predictive framework to be used during the development of a new drug candidate has not been reached.
Cryopreserved human hepatocytes suspended in well defined serum free media have been used to estimate TDI parameters for diltiazem, verapamil, erythromycin, clarithromycin, and troleandomycin, and combined with the Simcyp population-based ADME simulator to accurately predict CYP3A mediated DDIs (Xu et al., 2009) . The value of this approach in predicting reversible inhibition was not assessed by these authors. Cryopreserved human hepatocytes suspended in human plasma (HHSHP) represent a convenient, integrated metabolic environment for estimating the extent and mechanism of human DDIs. Lu et al. (Lu et al., 2007; DMD # 36400 5 2008a; Lu et al., 2008b) have utilized the HHSHP system to quantitatively determine the inhibition of various P450s by ketoconazole and fluconazole. Using this information, CYPmediated changes in the area under the curve (AUC) of several victim drugs were predicted accurately for DDIs involving these two prototypical competitive inhibitors, but the applicability to mechanism based inhibitors (MBI) was not addressed. Compared to in vitro systems using HLM, human hepatocytes suspended in human plasma inherently account for several parameters: 1) the plasma protein and microsomal binding of drug, 2) compound availability to the enzyme in its native environment within the cell and 3) metabolism of the compound by both CYP and non-CYP pathways including the potential for the formation of inhibitory metabolites.
The primary objective of the current study using HHSHP is to quantify the ability of a simple, single incubation time method to assess the CYP3A inhibition by a test compound in order to predict clinical DDIs without the knowledge of inhibition mechanism. A secondary aim is to identify the inhibition mechanism and compare the clinical DDI prediction based on the appropriate mechanistic models to those from the single incubation time method. Hepatocyte studies. Hepatocytes (pool of five individuals) were thawed in InVitro GRO TM HT Medium (25 ml per 5 million hepatocytes) and centrifuged at 50g at room temperature for 5 min.
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Materials and Methods
Materials
The cell pellet was reconstituted in HMM, and cell viability was found to be at least 80% using a
Vi-Cell XR cell viability analyzer (Beckman Coulter Inc., Brea, CA). After the cell viability was determined, hepatocytes were centrifuged at 50g at room temperature for 5 min and resuspended in human plasma (2x10 6 cells/ml). The cell suspension was incubated at 37 °C with 5% CO 2 until the addition of putative enzyme inhibitors.
Inhibition studies. The final inhibitor concentrations in human plasma were 0.13-100 µM for aprepitant, fluconazole, voriconazole, clarithromycin, conivaptan, diltiazem, erythromycin, itraconazole, nefazodone and troleandomycin, 0.03-20 µM for ketoconazole and ritonavir, and 0.07 to 50 µM for saquinavir. The final organic vehicle concentration was 0.5% methanol. The incubations were performed in triplicate. Stock hepatocyte suspension (25 µl) was added to 50 µl of inhibitor-containing plasma such that the final concentration of hepatocytes was 0.5×10 Liquid chromatography/tandem mass spectrometry methods. Quantification of 1'-OH midazolam was achieved using HPLC (Shimadzu LC10) interfaced to a triple quadrapole mass spectrometer (Sciex API 4000, Applied Biosystems, Foster City, CA). Chromatographic separation was achieved using a reverse phase column (Synergi Hydro-RP 4 µm column, 100 × 2 mm, Phenomenex, Torrance, CA) with a gradient consisting of 5% methanol in 5 mM ammonium acetate (mobile phase A) and 95% methanol in 5 mM ammonium acetate (mobile phase B) at a flow rate of 0.4 mL/min with a 25 µl injection volume. Specifically, 70% of mobile phase B was increased linearly to 80% from 0 to 2 min, and increased to 100% in the next 0.05 min. Mobile phase B was held at 100% from 2.05 to 2.30 min, and the column was re-equilibrated to 70% B. OH midazolam, respectively, per 100 µL well incubation. The interday accuracy ranged from -4.97% to 10.26%, and the intraday accuracy ranged from -6.13% to 11.09%. The interday precision ranged from 2.47% to 8.15%, and the intraday precision ranged from 1.70% to 13.15%.
Data analysis.
Inhibition data. The relationship between CYP3A activity at a given time and inhibitor concentration relative to baseline CYP3A activity was used to determine an IC 50 . All data were and V 35+t, [0] was estimated by Models A-C (Eq. 2-4).
[I] is the nominal inhibitor concentration, assuming no inhibitor depletion during the incubation. K I is the inhibitor concentration required for the half maximal inactivation, k inact is the maximum inactivation rate constant, and K i is the reversible inhibition equilibrium constant.
All raw data were fitted to Model A. If the parameters K i , k inact and K I with less CV% were estimated by Model A from the simultaneous fitting three sets of data corresponding to the ratio of 1'-OH midazolam formation rate versus inhibitor concentrations using weighted nonlinear regression, it suggested that the compound is a reversible and time dependent inhibitor.
For compounds which Model A was able to estimate the inactivation parameters (K I and k inact ) but not the reversible inhibition constant K i , the raw data were fitted to Model B which only estimates the inactivation parameters (K I and k inact ). For compounds which Model A was able to estimate the reversible inhibition constant K i but not the inactivation parameters (K I and k inact ), the raw data were fitted to Model C which only estimates the reversible inhibition constant K i.
Predictions of drug-drug interactions.
The single incubation time method A generic model (Eq. 5) of enzyme inhibition was used to predict a potential increase in exposure to a drug as a result of the inhibition of hepatic and intestinal CYP3A (Ito et al., 1998; Wang et al., 2004; Obach et al., 2006) . All assays were performed at a substrate concentration close to the K m of midazolam (data not shown). The inhibition mechanism may be unknown for some inhibitors nevertheless the assumption that K i, app = IC 50 /2 was applied (Obach et al., 2007) . For competitive inhibitors, the K i, app would be equivalent to the inhibition constant K i . In the case of TDIs that display mechanism based inhibition, K i, app would be equivalent to K I × k deg /k inact when [I] << K I (Wang et al., 2004) . (Ernest et al., 2005; Obach et al., 2006) .
[I] is collected from three main sources (details in the Supplemental Table 1 ). The average systemic plasma concentration of the inhibitor (plasma concentration area under curve from 0 to the dosing interval (AUC 0-τ ) divided by the dosing interval) observed or calculated in the primary literature was preferred. In some cases this was not available and then the plasma inhibitor concentration at a certain time point (eg. when the victim drug was administered) reported in the primary literature was employed. If the inhibitor concentration was not reported in the primary literature, values were obtained from secondary literature sources (Einolf, 2007; Fahmi et al., 2008; Fahmi et al., 2009) . These values were previously derived from other literature in which similar dosing regimens were employed for individual inhibitors. The IC 50 values are based on total inhibitor concentration in plasma and consequently there is no need to use unbound
This article has not been copyedited and formatted. The final version may differ from this version. based on the assumption that 1) no significant protein binding in the gut lumen and 2)
inhibitors not subject to any first pass metabolism (Rostami-Hodjegan A, 2004; Galetin et al., 2008) :
In which D is the dose of the inhibitor (mg), k a is the oral absorption rate constant of the inhibitor, ). An F a value of 1 was used for all drugs (Einolf, 2007 ).
In the current investigation, there were 12 clinical studies in which victim drugs were given intravenously. Among these 12 studies, midazolam was the victim drug in eleven clinical studies and the inhibitors were ketoconazole, aprepitant, conivaptan, voriconazole, troleandomycin, erythromycin, clarithromycin, diltiazem and saquinavir. In the other clinical study, fentanyl was the victim drug and ritonavir was the inhibitor. For these 12 studies, the AUC ratio was predicted using Eq. 7, in which the hepatic extraction ratio (EH) of the victim drug is accounted for in the DDI prediction (Kirby and Unadkat, 2010). Midazolam was assignedan EH of 0.4 (mean value calculated from the eleven clinical studies) and fenatanyl was assigned a value of 0.7 (Olkkola et al., 1999) .
(Eq. 7)
( )
The mechanistic method According to the inhibition mechanism, the magnitude of DDIs involving each inhibitor was predicted using the appropriate models.
For drugs identified as reversible inhibitors, AUC ratios were calculated by Eq. 5, where K i,app was equal to the K i estimated by Model C.
For drugs identified as TDIs with Model B, AUC ratios were calculated using the following equation (Mayhew et al., 2000; Wang et al., 2004) .
( Eq. 8) where k deg is the first-order rate constant of in vivo degradation of the affected enzyme. The values of k deg used for intestinal (k deg, CYP3A, g ) and hepatic CYP3A (k deg,CYP3A,h ) were 0.000481 ( t 1/2 = 24 h ) and 0.000321 min -1 ( t 1/2 = 36 h ), respectively (Wang et al., 2004; Obach et al., 2007; Quinney et al., 2010; Wang, 2010) . For the 12 clinical studies involving IV administration of the victim drug, the AUC ratio was predicted using Eq. 9 (Kirby and Unadkat, 2010).
(Eq. 9)
For drugs identified as reversible and time dependent inhibitors with Model A, the AUC ratio was calculated using Eq. 9 (Fahmi et al., 2008) . For the ritonavir and IV fentanyl DDI, the AUC ratio was predicted using Eq. 11 (Kirby and Unadkat, 2010) . 
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Results
Enzyme inhibition parameter estimation
The thirteen known CYP3A inhibitors represented reversible inhibitors (ketoconazole as strong reversible inhibitor and fluconazole as a moderate inhibitor) and TDIs (TAO as a strong TDI, diltiazem as a moderate TDI, and erythromycin as a weak TDI) that displayed a wide range of plasma protein binding (itraconazole and ketoconazole high protein binding, voriconazole and clarithromycin moderate protein binding, and fluconazole low protein binding). These inhibitors were incubated with human hepatocytes suspended in human plasma for 20 min over a range of concentrations in the absence of midazolam and a further 35 min in the presence of midazolam (30 µM). The IC 50 value for each inhibitor was estimated using Eq. 1 and the values are shown in Table 1 . For ketoconazole and fluconazole, the IC 50 values obtained here were similiar to those observed by Lu et al. using a comparable procedure (Lu et al., 2007; Lu et al., 2008a; Lu et al., 2008b) . Based on the assumption that the nominal concentration of inhibitor is close to the extracellular concentration, these IC 50 values represent the total (bound and unbound) concentration of the inhibitors that inhibit 50% of CYP3A activity and consequently there was no correction of fraction unbound in plasma for the IC 50 values. As shown in Table 1 , ritonavir was the most potent inhibitor with the lowest IC 50 value, while aprepitant had the highest IC 50 value among the 13 drugs studied. In additional studies, incubation times of 0, 10 and 20 min (with inhibitors alone) were used to generate IC 50 values (Table 1 ). The IC 50 value at the 20 min in the two independent studies showed very good agreement (Table 1) .
To define the inhibition mechanism for each inhibitor, models of reversible inhibition Table 2 . The process of defining the inhibition mechanism took place in the following three steps.
First, all raw data were fitted to the combined reversible plus irreversible model (Model A). The fit of Model A indicated that ketoconazole is a reversible inhibitor but not a TDI because Model A was able to estimate the reversible inhibition constant K i but not the inactivation parameters (K I and k inact ). This observation was also the case with fluconazole, aprepitant and voriconazole, which is not unexpected because these compounds are all known reversible inhibitors (Ito et al., 1998) . A second group of compounds (erythromycin, nefazodone, troleandomycin, clarithromycin, diltiazem, itraconazole and saquinavir) were identified as TDI only, because Model A was able to estimate the inactivation parameters (K I and k inact ) for each with reasonable precision but not the reversible inhibition constant K i . Ritonavir represents a potential third group of compounds as it was suggested to be a reversible and time-dependent inhibitor because both the reversible inhibition constant K i and the inactivation parameters (K I and k inact ) were well estimated ( Fig. 1d and Table 2 ).
In the second step of assigning a mechanism, inhibitors which were initially assigned as TDIs only were further analyzed using the model for irreversible inhibition (Model B), which only estimates the inactivation parameters (K I and k inact ). Better fitting of the data and more precise (less CV%) estimates of inactivation parameters of these inhibitors (TDI only) were obtained utilizing Model B (Fig. 1b-c % CV). In addition, Model C also fitted the ritonavir data well, which was not surprising as the compound was reported as a very potent reversible as well as a TDI in HLM (Ernest et al., 2005) .
Thus, the inhibition constants of ritonavir estimated from both models have been included in Table 2 .
Prediction of DDIs
The in vitro inhibition constants for the thirteen CYP3A inhibitors studied were used to predict 52 clinical DDIs (Table 3) (Table 3) ; [I] g was calculated using Eq.6. The predicted and observed AUC ratios are listed in Table 3 , and a plot of predicted DDIs versus observed values from clinical studies is shown in interactions (100% accuracy) (Fig. 2) . Using the criteria of within 2-fold of the observed value for an accurately predicted DDI, this approach correctly predicted 44 out of 52 clinical DDIs (85% accuracy) (Fig. 2) . The predictions for the remaining outliners (8 out of 52) were within-3 fold of the observed values and included 2 cases for fluconazole, 2 case for voriconazole, 2 cases for saquinavir, and 2 cases for clarithromycin. There were no false positive or false negative predictions.
The mechanistic method: utilizing in vitro parameters estimated by Models A-C
As described in Materials and Methods, each DDI was also predicted according to the inhibition mechanism of the compound. Predicted AUC ratios are listed in Table 3 clinical DDIs (88% accuracy) within 3-fold (Fig. 3) . Predictions that were more than 3-fold different from observed values involved 1 case for saquinavir, 1 cases for erythromycin, 1 case for clarithromycin, 1 case for diltiazem and 2 cases for conivaptan. There were no false positive or false negative predictions.
This article has not been copyedited and formatted. The final version may differ from this version. investigated six drugs (miconazole, ketoconazole, fluconazole, quinine, fluoxetine and fluvoxamine) in both rat micosomes and freshly isolated rat hepatocytes, and indicated that these systems gave similar estimates of inhibitory potency after correction for the nonspecific binding in each system for these CYP3A inhibitors. However, although all three studies noted above (Zhao et al., 2005; McGinnity et al., 2006; Brown et al., 2007) compared the in vitro inhibition parameters generated from microsomes to those from hepatocytes, the question of whether the parameters generated from hepatocytes resulted in an improved ability to predict human DDIs was not addressed. Xu et al. (2009) observed clinical DDIs involving two known CYP3A inhibitors, ketoconazole and fluconazole (Lu et al., 2007; Lu et al., 2008a; Lu et al., 2008b) . In the present report, the utility of cryopreserved human hepatocytes suspended in human plasma to predict in vivo DDIs was further explored using 13 reversible and TDIs of CYP3A and midazolam as the probe substrate.
The approach to predict CYP3A DDI prediction utilized in the current report did not focus on an initial characterization of the mechanism of inhibition but rather employed a single IC 50 measurement in hepatocytes suspended in human plasma; an analogous approach has been described in the HLM system (Obach et al., 2007; Grime et al., 2009; Burt et al., 2010) . This single incubation time method captures both reversible and TDI by using appropriate experimental conditions. In these studies, 0.5x10 6 cryopreserved hepatocytes per ml were used because this is similar to 0.17 mg/ml HLM protein, a concentration commonly used in studies in The results presented demonstrate that an IC 50 value generated from a single incubation time was able to adequately predict the magnitude of an in vivo DDI (Table 3 , Fig. 2 ). This IC 50
This article has not been copyedited and formatted. The final version may differ from this version. value is combined with the total average systemic plasma concentration of the inhibitor in a predictive model that incorporates the fraction of the victim drug cleared by CYP3A, and intestinal availability of the victim drug (Eq. 5). This differs from previous approaches wherein the mechanism(s) of inhibition needs to be identified prior to the parameter estimation in vitro and DDI prediction in vivo. This single incubation time method was able to predict 85 % of 52 clinical CYP3A DDI studies within 2-fold of the observed change in AUC regardless of the inhibition mechanism (Fig. 2) . The high rate of successful prediction of DDI suggests that this relatively simple, mechanism independent approach will be of great use to determine the potential for CYP3A mediated DDIs for new candidates and previously uncharacterized molecules. This single incubation time approach to predicting DDIs may be particularly useful for molecules with a potential for exhibiting TDI in the early discovery stage when the standard time-consuming process of estimating the inactivation parameters (K I and k inact )
in HLM may not be feasible. Although the single time point method may not provide the inhibition mechanism, it was able to accurately predict the DDIs related to 8 TDIs.
Among these 8 TDIs, itraconazole is believed to exhibit TDI due to the inhibitory metabolite formation (Isoherranen et al., 2004; Kunze et al., 2006; Quinney et al., 2008a; Templeton et al., 2008) whereas the remaining seven TDIs were known to display MBI. The potential of predicting the interaction due to the inhibitory metabolite formation without synthesizing and testing the metabolite is an important feature of this model particularly useful in the discovery phase of the development of a new chemical entity, since identification of the exact structure of the metabolite often may not be available in early discovery.
It is well known that the expression of CYP3A enzymes in enterocytes results in significant presystemic intestinal metabolism of drugs and possible gut wall DDIs after oral administration (Schwenk, 1988; Kaminsky and Fasco, 1991; Paine and Oberlies, 2007) . Clinical studies included in the dataset used in this investigation showed that ketoconazole, voriconazole, This article has not been copyedited and formatted. The final version may differ from this version. for the victim drug) represent the population in a specific clinical DDI study.
Although there is no need to correct the systemic plasma concentration [I] with f u,p for the hepatic interaction prediction when the K i,app values generated from hepatocytes plasma were utilized, the f u,p value was used to correct the K i,app for the intestinal interaction prediction because entocytes are considered as plasma protein-free environment. It is worthwhile to note that the intestinal inhibitor concentration calculated from the current model often exceeds the solubility of these drugs in intestinal fluid and generally is much higher than the K i,app before any f u,p correction
. As a result the inhibitors examined in this study are predicted to completely inhibit the CYP3A in gut wall over the time during which the victim drugs are absorbed. Therefore, the final intestinal DDI prediction depends only on the value of F g . This point is illustrated in Figure   4b , where there is no f u,p correction for the K i,app in the intestinal interaction and the outcome of DDI prediction was similar to the performance when f u,p was employed. One exception to this general observation was the case of aprepitant, which displays high a K i,app value and a f u,p correction is needed for the optimal prediction of the intestinal wall DDI component.
Following initial identification of inhibitors and DDI prediction by single incubation time method, it may be desirable when examining new compounds to characterize the inhibition mechanism and estimate specific enzyme inhibition parameters. In the mechanistic approach, the incubation times with the inhibitor are 0, 10 and 20 min, and three IC 50 curves are generated. All the data are incorporated into three models A-C (Eqs. 2-4) which are designed to differentiate reversible inhibitors, TDIs and inhibitors with both properties. These models were used to and incorporated into corresponding equations. With the knowledge of inhibition mechanism, 65% of 52 clinical DDIs were accurately predicted within 2-fold of the observed fold change in AUC (Fig. 3) .
The results reported here on the prediction of CYP3A DDIs using inhibitory parameters generated with human hepatocytes suspended in human plasma demonstrated that this robust system overcomes a number of perceived weaknesses associated with other in vitro approaches.
In particular this model provides an integrated cellular environment in which all modes of hepatic metabolism are retained and the uncertainty in concentration of inhibitor at the enzyme is greatly reduced. The single incubation time method simply requires a single inhibition parameter to predict the DDI caused by CYP3A inhibition, and there is no need to correct for nonspecific binding. Furthermore, in these predictions the total average systemic plasma concentration of the inhibitor provides a reasonable value for both reversible inhibitors and TDIs without the need for the determination of fraction unbound in plasma to calculate unbound drug concentrations. The study design for inhibition using HHSHP has been simplified such that there is only one time point, no dilution step (often performed with TDIs in HLM incubation) and the same midazolam concentration (close to its K m ) is used in all IC 50 assessments. This simple protocol design is achievable due to the fact that Model A has demonstrated the capability to extrapolate the reversible and time dependent inhibition properties simultaneously.
In summary, cryopreserved human hepatocytes suspended in human plasma were determined to be a robust and reliable system for the prediction of CYP3A DDIs. These predictions may be made by utilizing an IC 50 determined at a single incubation time regardless of the inhibition mechanism, and if needed, mechanism may also be explored with the mechanistic method.
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